glp gip tirzepatide Eli Lilly's GIP/GLP-1 Dual Agonist Tirzepatide: Lowering Blood Sugar, Weight, And Cardiovascular Risk! - Industry news - News Bumps and humps in the

Description

Let's explore this

GLP-1s have been a major theme this year, positioned as catalysts for reimagining care for interconnected conditions

Here's what utilization, side effects, persistence, and comparative effectiveness actually mean.

Check out the full study in Nature and our new GLP-1 report here: / / #Genetics #GLP1 #PrecisionMedicine #Biotech #23andMe #HealthTech

The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status